IO Biotech (IOBT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IOBT · Stock Price

USD 0.00-1.00 (-99.60%)

Market Cap: $288K

Historical price data

Market Cap: $288KPipeline: 3 drugsFounded: 2012Employees: 51-200HQ: Copenhagen, Denmark

Sector Ranking#77 in Immunotherapy / Immuno-Oncology #167 in Oncology (General)

Overview

IO Biotech's mission is to develop immune-modulatory cancer vaccines that transform 'cold' tumors into 'hot,' immune-responsive environments. The company's lead candidate, IO102-IO103, has completed a pivotal Phase 3 trial in first-line advanced melanoma in combination with pembrolizumab. Its strategy leverages a differentiated T-win® platform to create combination-friendly, off-the-shelf therapies that could potentially enhance the efficacy of established immunotherapies.

OncologyImmunology

Technology Platform

The T-win® platform designs off-the-shelf peptide vaccines that stimulate T cells to kill tumor cells and immune-suppressive cells expressing targets like IDO1 and PD-L1, thereby reprogramming the tumor microenvironment to enhance anti-tumor immunity.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
IO102/IO103 + Nivolumab-Relatlimab	Melanoma	Phase 2
PD-L1 peptide	Smoldering Multiple Myeloma	Phase 2
PD-L1/IDO Peptide Vaccine + Pembrolizumab	High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma	Phase 1

Funding History

3

Total raised:$187M

IPO$100MUndisclosedJun 25, 2021

Series B$67MHBM Healthcare InvestmentsDec 15, 2020

Series A$20MNovo HoldingsSep 15, 2018

Opportunities

Positive Phase 3 data in first-line melanoma could validate the T-win® platform, unlock a multi-billion dollar market opportunity, and drive expansion into other CPI-sensitive tumors like NSCLC and bladder cancer.

The off-the-shelf nature of the vaccine offers a significant commercial and logistical advantage over personalized therapies.

Risk Factors

The company faces binary clinical risk from its Phase 3 trial readout, significant financial risk as a pre-revenue micro-cap requiring further funding, and intense competition in the immuno-oncology combination therapy landscape from larger, better-resourced companies.

Competitive Landscape

IO Biotech competes with other CPI combination therapies (e.g., anti-CTLA-4, LAG-3 inhibitors) and therapeutic cancer vaccine approaches. Its key differentiation is the T-win® mechanism of targeting immune-suppressive cells to modulate the TME, rather than directly targeting tumor antigens, positioning it as a potential universal combination partner for checkpoint inhibitors.